1. Pink Sheet
  3. >>North America
  4. >>United States

DTC Rx Drug Ad Study No. 30: Do Market Claims Impact Perception?

 
• By Brenda Sandburg

FDA to assess whether claims such as '#1 prescribed' affect consumer views of drug product; project to cost $529,742. Chart notes price tag for 18 other DTC studies.

Do print ads touting a prescription drug as “new” or “#1 prescribed” impact consumer perceptions of a product? That’s the question FDA aims to answer in its latest study of direct-to-consumer Rx drug advertising.

The study, “Market Claims in Direct-to-Consumer Prescription Drug Print Ads,” will assess the impact of market claims on perceptions with and without quantitative information about product efficacy. FDA announced the study in a July 20 Federal Register

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

HHS Secretary Kennedy Says Trump Will Make Final Decision On Mifepristone Policy

 
• By Derrick Gingery

With an FDA review ongoing, Kennedy’s admission, made during a Senate hearing on the Health and Human Services Department’s budget request, suggests political officials could supersede scientific decisions.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.